Aquestive Therapeutics, Inc.
AQST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001398733
In the last 90 days, Aquestive Therapeutics, Inc. insiders filed 1 open-market purchase and 4 sales; 185 institutions reported holding it in 13F filings for Q2 2026, worth $299.5M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 12, 2026
- $448.7M
- Insider buysLast 90 days, $99.3K in total
- 1
- Insider sellsLast 90 days, $378.9K in total
- 4
- 13F holdersQ2 2026, +6 vs. previous quarter
- 185
- 13F valueReported value at the end of Q2 2026
- $299.5M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $44.5M
- −22.6% year over year
- Net income, FY2025
- -$83.8M
- No comparable prior period
- Free cash flow, FY2025
- -$53.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $7.56M
- −41.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $83.8M (188.1% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 29.3M
- Shares sold short
- Change
- +1.72M
- +6.2% vs. previous
- Days to cover
- 13.24
- At average daily volume
Superinvestors holding AQST, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding AQST at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Aquestive Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2026 (view filing)11:59 AM ET | Nov 10 | 2 days | Daly Richard JDirector | PPurchase | +28.0K | $3.54 | +$99.3K | New position28.0K after | 2 lots |
| Oct 16, 2026 (view filing)2:17 PM ET | Oct 15 | 1 day | Barber DanielPresident and CEO | SSale | −25.0K | $4.22 | −$105.6K | −3.8%627.3K after | 10b5-1 |
| Sep 16, 2026 (view filing)2:00 PM ET | Sep 15 | 1 day | Barber DanielPresident and CEO | SSale | −25.0K | $4.82 | −$120.5K | −3.7%652.3K after | 10b5-1 |
| Sep 11, 2026 (view filing)11:07 AM ET | Sep 9 | 2 days | Korczynski SherryChief Commercial Officer | SSale | −8.75K | $5.22 | −$45.7K | −3.6%235.7K after | 10b5-1 |
| Aug 18, 2026 (view filing)4:13 PM ET | Aug 17 | 1 day | Barber DanielPresident and CEO | SSale | −25.0K | $4.29 | −$107.2K | −4.1%585.6K after | 10b5-1 |
| Jul 17, 2026 (view filing)1:15 PM ET | Jul 15-16 | 2 days | Barber DanielPresident and CEO | SSale | −25.0K | $4.01 | −$100.2K | −3.9%610.6K after | 2 lots10b5-1 |
| Jun 24, 2026 (view filing) | Jun 23 | 1 day | Krop JulieDirector | SSale | −25.0K | $5.02 | −$125.5K | −100.0%0 after | 10b5-1 |
| Jun 16, 2026 (view filing) | Jun 15 | 1 day | Barber DanielPresident and CEO | SSale | −25.0K | $4.16 | −$104.0K | −3.8%635.6K after | 10b5-1 |
| May 18, 2026 (view filing) | May 15 | 3 days | Barber DanielPresident and CEO | SSale | −8.26K | $4.29 | −$35.4K | −1.2%660.6K after | 10b5-1 |
| Mar 11, 2026 (view filing) | Mar 10 | 1 day | Boyd Peter E.Chief People Officer | SSale | −29.8K | $4.17 | −$124.3K | −8.1%338.5K after |
Top 10 13F holders, Q2 2026
See all 185 holdersThe largest institutional positions in Aquestive Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bratton Capital Management, L.P. | 9,810,958 | $40.8M | 100.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 8,069,373 | $33.6M | 0.00% | +560,302+7.5% | Added |
| RTW Investments, LP | 7,426,471 | $30.9M | 0.26% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 4,584,533 | $19.1M | 0.00% | +140,835+3.2% | Added |
| Federated Hermes, Inc. | 3,112,561 | $12.9M | 0.02% | +172,222+5.9% | Added |
| State Street Corp | 2,928,020 | $12.2M | 0.00% | +381,829+15.0% | Added |
| Geode Capital Management, LLC | 2,622,888 | $10.9M | 0.00% | +214,697+8.9% | Added |
| Samsara BioCapital, LLC | 2,500,000 | $10.4M | 0.85% | 00.0% | Unchanged |
| Bank of America Corp | 1,668,423 | $6.94M | 0.00% | −736,627−30.6% | Reduced |
| Sio Capital Management, LLC | 1,486,175 | $6.18M | 1.06% | −436,712−22.7% | Reduced |
Holders of 5% or more of AQST
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Aquestive Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Bass Edward P | 13G | 7.50%9.39M shares | New | Oct 7, 20261 filing | Oct 7, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.40%7.99M shares | +1.10 ppfrom 5.30% | Oct 22, 20244 filings | Jul 27, 2026 | SEC |
| RTW Investments, LP | 13G | 5.20%6.25M shares | New | Nov 14, 20251 filing | Nov 14, 2025 | SEC |